Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk

CompletedOBSERVATIONAL

Enrollment

645

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

September 13, 2023

Study Completion Date

September 13, 2023

Conditions

Coronary Artery Disease (CAD)Peripheral Arterial Disease (PAD)

Interventions

DRUG

Rivaroxaban 2.5 MG [Xarelto]

rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD

Trial Locations (12)

Jeroen Bosch hospital, 's-Hertogenbosch

OLVG, Amsterdam

Rijnstate hospital, Arnhem

Medisch Spectrum Twente, Enschede

Zuyderland Medical Center, Heerlen

Isala Klinieken, location Meppel, Meppel

St. Antonius hospital, Nieuwegein

Haaglanden Medisch Centrum, The Hague

Hagaziekenhuis, The Hague

Elisabeth-Tweesteden hospital, Tilburg

VieCuri, Venlo

Isala hospital, Zwolle

All Listed Sponsors

collaborator

Diagram B.V.

OTHER

lead

Maatschap Cardiologie Zwolle

OTHER

NCT04753372 - Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk | Biotech Hunter | Biotech Hunter